Zypitamag™ (pitavastatin) tablets: a pharmaceutical alternative to Livalo. Zypitamag was introduced to the U.S. market in 2017 to improve patient access to pitavastatin.
Zypitamag is covered for over 150 million Americans and is available to most patients at near generic pricing. Through our savings program, eligible patients receive the first 30-days of Zypitamag FREE followed by a $10/month co-pay. If patients are uninsured, Zypitamag is available at a price of $29/month for a 90-day prescription. Eligibility criteria apply.
Zypitamag is marketed by Medicure Pharma, which is focused on the development and commercialization of cardiovascular therapeutics for the U.S. market. Medicure strives to become a leading specialty pharmaceutical company in the U.S. market by improving people’s lives through our growing product portfolio of cardiovascular products and innovative commercial model. Our commitment to service, partnership and integrity are what sets us apart.
Visit us at Medicure.com